WHO and colleagues
Key messages and partnerships to raise awareness and improve outcomes for people with asthma and COPD in LMIC
Article
01 Dec 2022
The availability, cost and affordability of essential medicines for asthma and COPD in LMIC: a systematic review, Lancet Global Health 2022
01 Oct 2022
This systematic review, commissioned by WHO, explored the availability, cost and affordability of essential medicines for asthma and COPD in LMICs in published literature between 2010-2022. Inhaled medicines were largely unavailable and unaffordable – this was particularly true for inhalers containing corticosteroids.
